Form 4: Charles River Labs Executive Shannon M. Parisotto Reports Stock and Options Transactions

Shannon M. Parisotto, a CEVP at Charles River Laboratories, reported the acquisition of restricted stock units and stock options, along with holdings through Karpathos Investments LLC.

Summary

• On May 31, 2024, Shannon M. Parisotto, CEVP at Charles River Laboratories International, Inc., reported transactions involving the company's stock.
• Parisotto acquired 1,727 shares of common stock through unvested restricted stock units.
• These restricted stock units vest in installments: 431 on May 31, 2025, 432 on May 31, 2026, 432 on May 31, 2027, and 432 on May 31, 2028.
• Parisotto also acquired 3,925 stock options with an exercise price of $208.44.
• These options vest in installments: 981 on May 31, 2025, 981 on May 31, 2026, 981 on May 31, 2027, and 982 on May 31, 2028, and expire on May 31, 2034.
• Following these transactions, Parisotto directly owns 8,406 shares of common stock and indirectly owns 26,529 shares through Karpathos Investments LLC.
• Parisotto also directly owns 3,925 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing of stock and option transactions. The acquisition of shares and options by an executive is generally viewed as a positive signal, but it's not a strong indicator of significant positive or negative sentiment.

Positives

• The acquisition of stock and options by a company executive can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedules for the stock and options suggest a multi-year incentive plan for the executive.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies and are often used as a form of compensation and incentive. Monitoring these transactions can provide insights into management's perspective on the company's value and future prospects.

Comparison to Industry Standards

• Executive compensation packages, including stock options and restricted stock units, are standard practice among publicly traded companies, particularly in the biotech and pharmaceutical industries.
• Companies like Labcorp (LH) and Quest Diagnostics (DGX), which are competitors of Charles River Laboratories, also utilize similar equity-based compensation strategies for their executives.
• The vesting schedules and exercise prices are generally aligned with industry norms to incentivize long-term performance and retention.

Stakeholder Impact

• The transactions reported may have a minor impact on shareholders by slightly increasing the number of outstanding shares over time as options are exercised and restricted stock units vest.
• The equity-based compensation structure incentivizes the executive to work towards increasing shareholder value.

Key Dates